Penumbra, Inc. (NYSE:PEN - Get Free Report) CEO Adam Elsesser sold 16,560 shares of the business's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $274.35, for a total value of $4,543,236.00. Following the transaction, the chief executive officer now directly owns 63,911 shares of the company's stock, valued at $17,533,982.85. This represents a 20.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Adam Elsesser also recently made the following trade(s):
- On Wednesday, April 2nd, Adam Elsesser sold 16,565 shares of Penumbra stock. The stock was sold at an average price of $272.24, for a total value of $4,509,655.60.
- On Wednesday, March 19th, Adam Elsesser sold 16,600 shares of Penumbra stock. The shares were sold at an average price of $276.21, for a total value of $4,585,086.00.
- On Wednesday, March 5th, Adam Elsesser sold 61,600 shares of Penumbra stock. The stock was sold at an average price of $283.59, for a total transaction of $17,469,144.00.
Penumbra Stock Down 0.4 %
Shares of NYSE:PEN opened at $276.62 on Friday. The company has a market capitalization of $10.70 billion, a PE ratio of 813.60, a P/E/G ratio of 2.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company's fifty day moving average is $275.47 and its 200-day moving average is $251.25. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00.
Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million for the quarter, compared to analysts' expectations of $311.63 million. Equities research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have weighed in on PEN. UBS Group increased their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Robert W. Baird increased their target price on shares of Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Wells Fargo & Company boosted their price target on Penumbra from $275.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. boosted their price objective on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Penumbra currently has an average rating of "Moderate Buy" and a consensus price target of $293.93.
View Our Latest Report on PEN
Hedge Funds Weigh In On Penumbra
Institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC grew its holdings in shares of Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock worth $150,000 after purchasing an additional 39 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after acquiring an additional 41 shares during the last quarter. Baker Avenue Asset Management LP increased its position in Penumbra by 1.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock valued at $791,000 after acquiring an additional 53 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Penumbra by 1.0% in the fourth quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock worth $1,359,000 after acquiring an additional 57 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Penumbra by 16.4% during the first quarter. Fifth Third Bancorp now owns 404 shares of the company's stock worth $108,000 after purchasing an additional 57 shares in the last quarter. Institutional investors own 88.88% of the company's stock.
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
